Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Notches Up Approval For BELVIQ’s Sales In South Korea

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) unveiled to the world that it has received due information from sources at Ildong Pharmaceutical Co., Ltd., that the most popular drug BELVIQ® (lorcaserin HCl) has been approved for undue usage across the territories of South Korea by the Ministry of Food and Drug Safety. The drug is an exquisite one in the realm of weight management. Ildong is entrusted with the job to market and aptly distribute the medicine across South Korea.

Do analyst foresee a momentum shift in ARNA?

Previously, Ildong had arrived at an agreement pertaining to marketing and supply with the entire subsidiary, wholly owned by ARNA. In lieu of the connection or agreement and consequent approval, shall receive net payment of around $3 million from its partner in South Korea, Ildong.

BELVIQ And Weight Management

Obese or over weight individuals tend to opt for flab cutting techniques that revolve around reducing calorific diet intake and enhance the bodily (physical) activities. Weight management revolves around taking the apt precautions and implementing the methodologies to work towards reducing the Body Mass Index or BMI.

According to the globally accepted standards, individuals with 30Kg/sq. meter or higher BMI is considered as Obese, whereas, ones with 27 Kg/sq. meter with other adjunct diseases or comorbid conditions that comprise dyslipidemia, hypertension and Tyoe2 Diabetes. With the flab cutting methodologies being practiced, opting to consume BELVIQ is an apt move with regards to maintain bodily balance and help refrain from being affected by the scenario of accumulated weight.

CEO’s Concern

The CEO and President of ARNA commented that the team has expressed their content with the latest achievement garnered by Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), at the latest achievement. Jack Lief, the CEO communicated that the company has plans to notch up approval on a myriad of other additional territories and thereby emerge as a reliable and leading pharmaceutical house located in South Korea. Further, he hopes that Ildong shall come up with novel therapies to bolster BELVIQ’s sales in South Korea.

About the Author

Coper graduated from the University of Chicagi with majors in political science and journalism.

Leave A Response